Emerging phagocytosis checkpoints in cancer immunotherapy

Y Liu, Y Wang, Y Yang, L Weng, Q Wu… - Signal transduction and …, 2023 - nature.com
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Role of CD47 in hematological malignancies

E Eladl, R Tremblay-LeMay, N Rastgoo… - Journal of hematology & …, 2020 - Springer
CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by
nearly all cells of the body. It plays an integral role in various immune responses as well as …

Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy

H Tao, X Zhong, A Zeng, L Song - Frontiers in Immunology, 2023 - frontiersin.org
Lactate, traditionally regarded as a metabolic waste product at the terminal of the glycolysis
process, has recently been found to have multifaceted functional roles in metabolism and …

[HTML][HTML] Tumor-associated macrophages in multiple myeloma: advances in biology and therapy

J Sun, C Park, N Guenthner, S Gurley… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow (BM) and represents
the second most common hematological malignancy in the world. The MM tumor …

Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

Q Chen, X Guo, W Ma - Oncology Research, 2023 - pmc.ncbi.nlm.nih.gov
Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer,
with the tumor microenvironment (TME) playing a pivotal role in modulating the immune …

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

R Bouwstra, T van Meerten… - Clinical and Translational …, 2022 - Wiley Online Library
Background The CD47‐signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …

[HTML][HTML] Deciphering the role of CD47 in cancer immunotherapy

L Weng, Y Wang, J Zhang, Q Wu, P Zhao, Y Shi… - Journal of Advanced …, 2024 - Elsevier
Background Immunotherapy has emerged as a novel strategy for cancer treatment following
surgery, radiotherapy, and chemotherapy. Immune checkpoint blockade and Chimeric …

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy

K Alhallak, J Sun, K Wasden, N Guenthner, J O'Neal… - Leukemia, 2021 - nature.com
T-cell-based immunotherapy, such as CAR-T cells and bispecific T-cell engagers (BiTEs),
has shown promising clinical outcomes in many cancers; however, these therapies have …

Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment

S Kaur, KV Cicalese, R Banerjee… - Antibody …, 2020 - academic.oup.com
ABSTRACT CD47 is a ubiquitously expressed cell surface glycoprotein that functions as a
signaling receptor for thrombospondin-1 and as the counter-receptor for signal regulatory …

Immunotherapy of multiple myeloma: current status as prologue to the future

HN Abramson - International Journal of Molecular Sciences, 2023 - mdpi.com
The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …